Prediction and management of adverse events associated with the use of factor IX complex concentrates.
Prediction and management of adverse events associated with the use of factor IX complex concentrates.
复制标题
预测和管理与使用因子 IX 复合浓缩物相关的不良事件。
作者：
J. Lusher
在与抑制剂患者使用FIX CC相关的不良事件中，血液传播病原体的可能性现在大大降低。然而，必须意识到血栓性并发症和急性心肌梗死的可能性时，使用大，重复剂量的F IX CC。提高对这些潜在的危及生命的并发症的认识，避免频繁、重复的大剂量服用，应该会降低风险。F IX CC在使用抑制剂的血友病患者中并不总是有效地实现或维持止血。因此，在反应欠佳的受试者、需要手术干预的受试者或肌内肿块较大和/或需要长期治疗的受试者中，应考虑替代治疗方法。
Among the adverse events that have been associated with the use of F IX CC in inhibitor patients, the likelihood of transmission of blood-borne pathogens is now greatly reduced. However, one must be aware of the possibility of thrombotic complications and acute myocardial infarction when using large, repetitive doses of F IX CC. A greater awareness of such potentially life-threatening complications, and avoidance of frequent, repetitive large doses, should decrease the risk. F IX CC are not always effective in achieving or maintaining hemostasis in hemophiliacs with inhibitors. Thus, in subjects who are responding suboptimally, in those in need of surgical intervention, or in those who have large intramuscular hemorrhages and/or will require a prolonged period of treatment, alternative therapeutic approaches should be considered.